Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
Plus
15
Ṁ656Jan 1
74%
chance
1D
1W
1M
ALL
The rise of GPL-1 agonists as "miracle" drugs to cure obesity, hypertension, and a myriad of social issues related to an unhealthy body mass has been nothing short of stunning -- as important as the development of AI. But we are just learning about the other potential effects of these. Will a new clinical trial at least confirm what we think we know about this class of drugs?
Get
1,000and
1.00
1,0001.00Related questions
Related questions
Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
36% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
12% chance
Will Pfizer announce a weight loss drug competing with Ozempic and Wygovy before 12/31/2024?
35% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
Will there be medical consensus that GLP-1 drugs have cardiovascular benefits beyond those provided via weight loss?
71% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
80% chance
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
30% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
33% chance